公开(公告)号：EP3099332A1

公开(公告)日：2016-12-07

申请号：EP15742953.1

申请日：2015-01-29

申请人： Synta Pharmaceuticals Corp.

发明人： CHIMMANAMADA, Dinesh, U. ,  YING, Weiwen

IPC分类号： A61K47/48

CPC分类号： A61K47/481 ,  A61K31/365 ,  A61K31/395 ,  A61K31/436 ,  A61K31/56 ,  A61K31/69 ,  A61K47/55

摘要： The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

公开(公告)号：EP2298748B1

公开(公告)日：2016-07-20

申请号：EP10075452.2

申请日：2005-11-17

申请人： Synta Pharmaceuticals Corp.

发明人： Ying, Weiwen ,  James, David ,  Zhang, Shijie ,  Przewloka, Teresa ,  Chae, Junghyun ,  Chimmanamada, Dinesh U ,  Lee, Chi-Wan ,  Kostik, Elena ,  Ng, Howard P ,  Foley, Kevin ,  Du, Zhenjian ,  Barsoum, James

IPC分类号： C07D249/12 ,  C07D401/04 ,  C07D405/04 ,  C07D403/04 ,  A61K31/4196 ,  A61P35/00

CPC分类号： C07D249/08 ,  A61K31/4196 ,  C07D249/12 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D473/00 ,  C07D473/34

公开(公告)号：EP2790691A1

公开(公告)日：2014-10-22

申请号：EP12806824.4

申请日：2012-12-12

申请人： Synta Pharmaceuticals Corp.

发明人： GUO, Wei ,  VUKOVIC, Vojo

IPC分类号： A61K31/16 ,  A61K31/165 ,  A61K31/337 ,  A61K31/439 ,  A61K31/706

CPC分类号： A61K31/16 ,  A61K31/165 ,  A61K31/337 ,  A61K31/439 ,  A61K31/706 ,  A61K2300/00

摘要： The present invention is a method for treating non-small cell lung cancer in a subject in need thereof, comprising administering to the subject an effective amount of a bis(thiohydrazideamide) compound of formula (I): wherein the variables are defined herein. Furthermore, pharmaceutical compositions, combination therapies, and uses thereof are also provided in the present application.

公开(公告)号：EP2773345A1

公开(公告)日：2014-09-10

申请号：EP12783829.0

申请日：2012-11-01

申请人： Synta Pharmaceuticals Corp.

发明人： PROIA, David

IPC分类号： A61K31/4196 ,  A61K45/06 ,  A61P35/00 ,  A61K31/05 ,  A61K31/353 ,  A61K31/4745 ,  A61K31/675

CPC分类号： A61K31/4745 ,  A61K31/05 ,  A61K31/353 ,  A61K31/4196 ,  A61K31/675 ,  A61K45/06 ,  A61K2300/00

摘要： A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (la) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.

公开(公告)号：EP2729144A2

公开(公告)日：2014-05-14

申请号：EP12735423.1

申请日：2012-07-09

申请人： Synta Pharmaceuticals Corp.

发明人： EL-HARIRY, Iman ,  PROIA, David ,  VUKOVIC, Vojo

IPC分类号： A61K31/4196 ,  A61K31/4439 ,  A61P35/00

CPC分类号： A61K31/4196 ,  A61K31/337 ,  A61K31/417 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/675 ,  A61K33/24 ,  A61K45/06 ,  C07D403/04 ,  A61K2300/00 ,  A61K31/444

摘要： Methods of treating cancer with a compound of formulae (I) or (la) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (la). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (la); a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.

公开(公告)号：EP2714038A1

公开(公告)日：2014-04-09

申请号：EP12723814.5

申请日：2012-05-23

申请人： Synta Pharmaceuticals Corp.

发明人： PROIA, David ,  HE, Suqin

IPC分类号： A61K31/4196 ,  A61K31/675 ,  A61P35/00 ,  A61K45/06

CPC分类号： A61K31/4196 ,  A61K31/436 ,  A61K31/4745 ,  A61K31/675 ,  A61K45/06 ,  C07D403/04 ,  A61K2300/00

摘要： A pharmaceutical composition comprising an mTOR/PI3K inhibitor, and an Hsp90 inhibitor according to the following formulae (I) and (Ia) or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.

公开(公告)号：EP2678013A1

公开(公告)日：2014-01-01

申请号：EP12707012.6

申请日：2012-02-22

申请人： Synta Pharmaceuticals Corp.

发明人： FOLEY, Kevin, P. ,  PROIA, David

IPC分类号： A61K31/4196 ,  A61P35/00

CPC分类号： A61K31/675 ,  A61K31/4196 ,  A61K45/06 ,  A61N2005/1098

摘要： Methods for treating cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the following structural formula a tautomer, or a pharmaceutically acceptable salt thereof in combination with radiotherapy. The variables depicted in the structural formula are defined herein.

公开(公告)号：EP2663305A1

公开(公告)日：2013-11-20

申请号：EP12700765.6

申请日：2012-01-10

申请人： Synta Pharmaceuticals Corp.

发明人： PROIA, David ,  FRIEDLAND, Julie

IPC分类号： A61K31/4196 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/4196 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/69 ,  A61K45/06 ,  A61K2300/00

摘要： A composition comprising a proteasome inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder such as cancer in a subject in need thereof, using pharmaceutical combinations described herein.

公开(公告)号：EP2640385A1

公开(公告)日：2013-09-25

申请号：EP11793607.0

申请日：2011-11-18

申请人： Synta Pharmaceuticals Corp.

发明人： BLACKMAN, Ronald, K. ,  VUKOVIC, Vojo

IPC分类号： A61K31/4196 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/502 ,  A61K31/506 ,  A61K31/517 ,  A61K39/395 ,  A61P35/00 ,  A61K31/395

CPC分类号： C07K16/22 ,  A61K31/404 ,  A61K31/436 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/506 ,  A61K31/517 ,  G01N33/57484

摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.

公开(公告)号：EP2184994B1

公开(公告)日：2013-09-25

申请号：EP08794963.2

申请日：2008-07-31

申请人： Synta Pharmaceuticals Corp.

发明人： CHEN, Shoujun

IPC分类号： C07D333/22 ,  C07D333/38 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  A61K31/675 ,  A61P37/08

CPC分类号： A61K39/00 ,  C07D333/22 ,  C07D333/38 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14